My NCBISign In

Display Settings:

Format

Send to:

Choose Destination

    Arthritis Res Ther. 2008;10(3):207. Epub 2008 May 8.

    Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications.

    Sidiropoulos PI, Karvounaris SA, Boumpas DT.

    Department Rheumatology, Clinical Immunology and Allergy, University Hospital, Medical School, University of Crete, 1, Voules Str, Heraklion 71110, Greece. sidiropp@med.uoc.gr

    Subjects with metabolic syndrome--a constellation of cardiovascular risk factors of which central obesity and insulin resistance are the most characteristic--are at increased risk for developing diabetes mellitus and cardiovascular disease. In these subjects, abdominal adipose tissue is a source of inflammatory cytokines such as tumor necrosis factor-alpha, known to promote insulin resistance. The presence of inflammatory cytokines together with the well-documented increased risk for cardiovascular diseases in patients with inflammatory arthritides and systemic lupus erythematosus has prompted studies to examine the prevalence of the metabolic syndrome in an effort to identify subjects at risk in addition to that conferred by traditional cardiovascular risk factors. These studies have documented a high prevalence of metabolic syndrome which correlates with disease activity and markers of atherosclerosis. The correlation of inflammatory disease activity with metabolic syndrome provides additional evidence for a link between inflammation and metabolic disturbances/vascular morbidity.

    PMID: 18492218 [PubMed - indexed for MEDLINE]

    PMCID: PMC2483433

    Supplemental Content

    Click here to read Click here to read
    Write to the Help Desk